Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy

Ziwei Huang,Lou Zhong,Jianwei Zhu,Hua Xu,Wenjing Ma,Lilei Zhang,Yuntian Shen,Betty Yuen-Kwan Law,Fei Ding,Xiaosong Gu,Hualin Sun

DOI: https://doi.org/10.21037/atm-20-7269

IF: 3.616

2020-12-01

Annals of Translational Medicine

Abstract:BACKGROUND: The molecular mechanisms underlying denervated skeletal muscle atrophy with concomitant muscle mass loss have not been fully elucidated. Therefore, this study aimed to attain a deeper understanding of the molecular mechanisms underlying denervated skeletal muscle atrophy as a critical step to developing targeted therapy and retarding the concomitant loss of skeletal muscle mass.METHODS: We employed microarray analysis to reveal the potential molecular mechanisms underlying denervated skeletal muscle atrophy. We used <i>in vitro</i> and <i>in vivo</i> atrophy models to explore the roles of the interleukin 6 (IL-6), Janus kinase (JAK), and signal transducers and activators of transcription 3 (STAT3) in muscle atrophy.RESULTS: In this study, microarray analysis of the differentially expressed genes demonstrated that inflammation-related cytokines were markedly triggered and IL-6/JAK/STAT3 signaling pathway was strongly activated during denervated skeletal muscle atrophy. The high level of IL-6 enhanced C2C12 myotube atrophy through the activation of JAK/STAT3, while inhibiting JAK/STAT3 pathway by ruxolitinib (a JAK1/2 inhibitor) or C188-9 (a STAT3 inhibitor) significantly attenuated C2C12 myotube atrophy induced by IL-6. Pharmacological blocking of IL-6 by tocilizumab (antibody against IL-6 receptor) and pharmacological/genetic inhibition of JAK/STAT3 pathway by ruxolitinib/C188-9 (JAK/STAT3 inhibitor) and STAT3 short hairpin RNA (shRNA) lentivirus in tibialis anterior muscles could suppress muscle atrophy and inhibit mitophagy, and was accompanied by the decreased expression of atrophic genes (<i>MuRF1</i> and <i>MAFbx</i>) and autophagy-related genes (<i>PINK1</i>, <i>BNIP3</i>, <i>Beclin 1</i>, <i>ATG7</i>, and <i>LC3B</i>).CONCLUSIONS: Taken together, the results suggest that IL-6/JAK/STAT3 pathway may be a principal mediator in denervated skeletal muscle atrophy, meaning targeted therapy against IL-6/JAK/STAT3 pathway might have potential as a therapeutic strategy for prevention of skeletal muscle atrophy.

oncology,medicine, research & experimental